Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology guideline
Chaganti, Sridhar Fox, Christopher P Maybury, Bernard D Burton, Cathy Barrington, Sally F Illidge, Timothy Kalakonda, Nagesh Eyre, Toby A McKay, Pam Kuhnl, Andrea
Chaganti, Sridhar
Fox, Christopher P
Maybury, Bernard D
Burton, Cathy
Barrington, Sally F
Illidge, Timothy
Kalakonda, Nagesh
Eyre, Toby A
McKay, Pam
Kuhnl, Andrea
Abstract
Time to progression is the strongest predictor of outcome in relapsed diffuse large B-cell lymphoma. Second-line treatment with chimeric antigen receptor (CAR) T-cell therapy is recommended for patients with progression within 12 months of first-line chemoimmunotherapy. In patients with late relapse, platinum-based chemotherapy followed by high-dose chemotherapy with autologous stem cell rescue is recommended. In second relapse, CAR T-cell or CD3xCD20 bispecific antibody therapy is recommended in eligible patients. Other treatment options are available for less fit patients. Specific recommendations are made on diagnostic immunohistochemistry, bendamustine use and bridging to CAR T-cell therapy.
MIDER Authors
Date
2025-05-19
Type
Article
Subject
Drug therapy, Antibodies, Immunotherapy, Lymphoma, non-Hodgkin, Drug therapy
Collections
Citation
Chaganti S, Fox CP, Maybury BD, Burton C, Barrington SF, Illidge T, Kalakonda N, Eyre TA, McKay P, Kuhnl A, Cwynarski K, Davies AJ; BSH Committee. Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline. Br J Haematol. 2025 Jun;206(6):1593-1603. doi: 10.1111/bjh.20129. Epub 2025 May 19.
Journal / Source Title
British Journal of Haematology
DOI
10.1111/bjh.20129
PMID
40384597
Publisher
Wiley-Blackwell
Publisher’s URL
https://onlinelibrary.wiley.com/journal/13652141